Related Experiment Video
Updated: Mar 3, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.2K
Hypersensitivity to Carboplatin in Children with Malignancy
Antonio Ruggiero1, Daniela Rizzo1, Martina Catalano1
1Division of Pediatric Oncology, Catholic University of RomeRome, Italy.
Frontiers in Pharmacology
|April 28, 2017
Summary
Hypersensitivity reactions (HSRs) to carboplatin chemotherapy can occur in children with cancer. Early recognition and desensitization protocols are crucial for managing HSRs and continuing effective treatment.
Area of Science:
- Pediatric Oncology
- Clinical Pharmacology
Background:
- Carboplatin is effective for treating childhood cancers.
- Hypersensitivity reactions (HSRs) to carboplatin can disrupt treatment and affect outcomes.
Purpose of the Study:
- To review the incidence and clinical features of carboplatin-induced HSRs in pediatric cancer patients.
- To assess the impact of HSRs on treatment efficacy and patient outcomes.
Main Methods:
- Systematic literature search of PubMed (1987-2016) for studies on carboplatin HSRs in children.
- Analysis of data on incidence, clinical presentation, risk factors, and management strategies.
Main Results:
- Carboplatin HSRs range from mild to severe.
- Risk factors include cumulative dose, younger age, female sex, and history of allergies.
- Management includes drug cessation, premedication, or desensitization.
Conclusions:
- Clinicians must be aware of carboplatin HSRs in pediatric patients.
- Desensitization protocols offer a viable option to continue carboplatin therapy in sensitized patients.
- Effective management strategies are essential to maintain treatment intensity and improve patient outcomes.
More Related Videos
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
294
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
294
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
446
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
446
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
340
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340
01:01Hypersensitivity Reactions: Cytolytic Reactions
74
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
74
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
694
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
694
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
388
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388